HER2 and CDK4/6 are undoubted two most important biological targets for breast cancer. Anti-HER2 treatments enhance objective response and progression-free survival/disease-free survival as well as overall survival. Three CDK4/6 inhibitors consistently improve objective response and progression-free survival; however, overall survival data are waited. Optimization of chemotherapy and endocrine strategies remains an unmet need. Check point inhibitor-based immunotherapy combined with chemotherapy is a promising field, especially for triple-negative breast cancer.
CITATION STYLE
Hu, X., Huang, W., & Fan, M. (2017, April 28). Emerging therapies for breast cancer. Journal of Hematology and Oncology. BioMed Central Ltd. https://doi.org/10.1186/s13045-017-0466-3
Mendeley helps you to discover research relevant for your work.